?ÃÃà ³¤´ï1.8ÃõÃDNAè³£²øÃÃÃúÃÃÃÃéµ°°ÃÃÃÃóúÃáÃå¡£ºÃÃÃÃéµ°°ÃÃÃÃÃÃöà ÃÃÃÃÃ㬱»ÃÃêÃé³Ã¿ÃÃà ´«ÃÃÃÃû´úø°ûµÃ±Ã¹ÃÃà ´«ÃÃÃ룬¼´¡°Ãéµ°°ÃÃÃÃ롱£¬ÃÃÃÃøµ¼Ãö¨Ã¸°ûÃà ÃûòÃéïÃ÷¹ÃÃûùÃòµÃ±Ã´ï¡£Ãéµ°°ÃÃÃÃëµÃ¸Ã±ä³£¼ûÃø÷Ãü²²¡Ãã¬ÃçÃÃÃö¡¢ÃÃÃà ²¡¼°ÃÂ¥Ãõá£Ãò´Ã£¬Ã½¾¿ÃúÃü°²¡Ãùý³ÃÃÃì³ÃÃéµ°°ÃÃÃÃëÃö¨ÃõûúÃÃÃùÃÃÃê¡£µ°°ÃøÃå¾ÃÃöà Ãõ°°Ãî½âø»îÃ㬸ºÃðø°ûÃôó¶à Ãýµ°°ÃÃõýµ½â¡£Ãñé´æÃÃÃø÷ÃÃÃéïÃõÃ26S µ°°ÃøÃÃ¥ÃÃ20S ºÃÃôû¯¿à ãºÃ19S µ÷½Ã¿à ãÃé³Ã£¬´Ã»¯·ºÃû¯µÃÃïµÃ½µ½â¡£ÃÃõÃ÷ºÃû¯½éµ¼µÃµ°°Ã½µ½âµÃ·¢ÃÃÃÃ2004Ãê»ñµÃà µ±´¶û½±¡£´ÃÃ⣬»¹ÃÃÃÃPA28a/PA28bÃ÷êµ÷½Ã¿à ãµÃÃâÃõ°°ÃøÃ壬ÃÃPA28gÃé³ÃµÃPA28g-µ°°ÃøÃ壬Ãü°ÃÃPA200 Ã÷êµ÷½Ã¿à ãµÃPA200-µ°°ÃøÃå¡£2013Ã꣬Ãú¿ÃúÃñᲨ½ÃÃÃÃà ¶Ã·¢ÃÃPA200-µ°°ÃøÃ帺Ãð¾«Ã÷¢Ãú¼°Ãåø°ûDNAÃðÃùý³ÃÃÃÃÃÃÃõ£»¯£¨¶ø·Ã·ºÃû¯£©½éµ¼µÃºÃÃÃÃéµ°°Ã½µ½â£¨Cell, 2013£©£¬ ÃÃÃýÃÿÃç½ç¹ÃÃÃÃåø°ûÃéµ°°Ã²»½µ½âµÃÃÃÃá£
ü£º µ°°ÃøÃ弤»îÃòÃÃPA200ì³Ãêü¼°ÃÂ¥Ãùý³ÃÃÃÃéµ°°ÃÃÃÃëµÃÃö¨ÃÃ
Â
   Ãî½ü£¬ÃñᲨ½ÃÃÃ-½ªÃìü¸±½ÃÃÃÃà ¶Ã½øû²½½ÃþPA200-µ°°ÃøÃåì³ÃÃéµ°°ÃÃÃÃëÃö¨²¢ÃÃȼÃÂ¥Ã᣸ýá¹ûÃÃÃÃ2020Ãê11ÃÃÃÃTheranostics£¨SCIðÃìÃòÃÃ8.579£©ÃÃÃ÷¢±Ã£¬Ãâê¡°Proteasome activator PA200 maintains stability of histone marks during transcription and aging¡±¡£ÃñᲨ½ÃÃúÃÃÿý½ÃÃÃê¸ÃÃõù²Ã¬Ã¨Ã¶Ã÷Ã㬽ªÃìü¸±½ÃÃü°²©Ã¿ÃúÃÃë¡¢º«ÃÃ깲õÃûÃ÷ÃᣲÃÃëÃâû¹¤Ã÷µÃ»¹ÃÃÃ廪´óçµÃò¡Ã°½ÃÃúÃÃñ¾Ãþ²¨´óçµÃTomoki Chiba½ÃÃõ᣸ÃÃþ¿·¢Ã㬺ÃÃÃÃéµ°°ÃÃÃêü¹ý³ÃÃÃò»áè¹ýµ°°ÃøÃå½µ½â¡£½øû²½£¬ÃûÃýÃþÃÃPA200-µ°°ÃøÃå½éµ¼ÃÃÃâûÃéµ°°Ã½µ½â¹ý³Ã¡£¸üêÃÃêµÃÃã¬PA200µÃÃóýÃÃÃø¸Ã±äÃéµ°°ÃÃÃÃëH3K4me3¼°H3K56ac·Ã²¼Ã»ÃúÃÃöá£PA200µÃñç¼ÃÃÃø°û¼°Ã¡Ãó¸öÃÃ¥ÃÂ¥Ã㬵¼ÃÃÃâÃÃÃÃÃ㬽¹Ã㬲¢Ãõ¶ÃáÃóÃÃÃü¡£ ÃûÃû¹·¢Ãã¬PA200ÃýÃøÃõÃìôÃïBLM10òÃÃÃà Ãõ÷ÃÃÂ¥ÃÃÃ÷Ã㬠±ÃÃ÷ÃâûÃÃÃóÃýø»¯Ãøöñ£Ãá£
   ¸ÃÃþ¿Ãõ½¹ú¼ÃÃÃû¿Ãç»ù½ðïñ»á¡¢¿Ã¼¼²¿¹ú¼ÃÃõãÃ÷¢¼Ã»®¼°±±¾©ÃÃÃÃû¿Ãç»ù½ðïÃà ¹ÃÃîÿÃÃÃú¡£
   ÃÂÃÃô½Ã£ºhttps://www.thno.org/v11p1458.htm
版权与免责声明:本网页的内容由收集互联网上公开发布的信息整理获得。目的在于传递信息及分享,并不意味着赞同其观点或证实其真实性,也不构成其他建议。仅提供交流平台,不为其版权负责。如涉及侵权,请联系我们及时修改或删除。邮箱:sales@allpeptide.com